SAB Biotherapeutics

SABS

Market cap $22.1M

Overview Fund Activity

2.12 USD

0.00

0%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

2.10

-0.02

0.94%

1 day

0%

5 days

-2.3%

1 month

-1.85%

3 months

15.85%

6 months

32.5%

Year to date

-42.86%

1 year

-23.47%

5 years

-97.91%

10 years

-97.91%

About: SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Employees: 63

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

13% more capital invested

Capital invested by funds: $2.99M [Q1] → $3.38M (+$385K) [Q2]

3.23% less ownership

Funds ownership: 23.94% [Q1] → 20.71% (-3.23%) [Q2]

4% less funds holding

Funds holding: 26 [Q1] → 25 (-1) [Q2]

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$9

325% upside

Avg. target

$10.5

395% upside

High target

$12

466% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Chardan Capital Keay Nakae	$12	Buy Maintained	8 Aug 2025
HC Wainwright & Co. Emily Bodnar	$9	Buy Maintained	22 Jul 2025

See Analyst Rankings

Financial journalist opinion

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a multi-specific human anti-thymocyte immunoglobulin (hIgG) for delaying the onset and progression of autoimmune type 1 diabetes (T1D), today announced that it will present at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) being held September 15 – 19, 2025 at the VIECON - Vienna Congress & Convention Center in Vienna, Austria. The Company will have four oral presentations, as well as an INNODIA-hosted symposium at EASD.

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

Zacks Investment Research

SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

SAB Biotherapeutics (SABS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

Recently raised $175 million in oversubscribed private placement which included strategic investor Sanofi and top-tier biotech investors Strong cash position with completed financing extending operational runway until the middle of 2028 Achieved alignment with FDA on the design and advancement of Phase 2b SAF ety and E fficacy of human anti-thymocyte immuno G lob U lin SAB-142 AR resting progression of type 1 D iabetes (SAFEGUARD) study following a constructive Type B meeting SAFEGUARD study to initiate in Q3 2025 MIAMI, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of autoimmune type 1 diabetes (T1D), today announced financial results for the second quarter ending June 30, 2025, and reported on recent developments. Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We are extremely pleased to have recently raised $175 million in capital with oversubscribed participation which will enable us to fully fund the completion of our pivotal Phase 2b SAFEGUARD study for our lead candidate, SAB-142 for delaying the progression of type 1 diabetes.

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

SAB BIO Announces Oversubscribed $175 Million Private Placement

Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and Woodline Partners LP, and existing investors Sessa Capital, the T1D Fund, and ATW Partners Proceeds expected to fully fund completion of pivotal Phase 2b SAFEGUARD study evaluating SAB-142 for delaying progression of autoimmune T1D in newly diagnosed T1D patients (Stage 3) Company expects proceeds to extend cash runway into the middle of 2028 Potential for up to an additional $284 million of gross proceeds if milestone-based warrants exercised in full MIAMI, July 21, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying progression of autoimmune type 1 diabetes (T1D) in newly diagnosed autoimmune T1D patients, today announced that it has entered into a securities purchase agreement (the “Agreement”) with certain accredited and institutional investors to raise $175 million upfront in gross proceeds in an oversubscribed private placement financing. The private placement includes participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and Woodline Partners LP, and existing investors Sessa Capital, the T1D Fund, and ATW Partners.

SAB BIO Announces Oversubscribed $175 Million Private Placement

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments. Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We have made strong progress this quarter on our corporate strategy and mission to deliver a transformational therapy that can halt or delay the progression of type 1 diabetes.

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

SAB BIO Reports Full Year 2024 Operating and Financial Results

MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the fourth quarter of 2024 in addition to its full year financial results for the fiscal year ended December 31, 2024, and reported on recent accomplishments and anticipated milestones. Samuel J. Reich, Chairman and CEO of SAB BIO stated, “Our recent announcement of positive topline data for SAB-142, further strengthens our belief that SAB-142 has the potential to be the best in-class disease-modifying therapy for T1D.

SAB BIO Reports Full Year 2024 Operating and Financial Results

SAB BIO to Participate in Upcoming Investor Conferences

MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing SAB-142, a human anti-thymocyte immunoglobulin (hIgG) that potentially delays the onset or progression of type 1 diabetes (T1D), today announced that members of its management team will participate in the following investor conferences:

SAB BIO to Participate in Upcoming Investor Conferences

Why Is SAB BIO Stock Trading Lower On Tuesday?

On Tuesday, SAB BIO SABS released topline data from a Phase 1 trial of SAB-142 in a single-ascending dose among healthy volunteers.

Why Is SAB BIO Stock Trading Lower On Tuesday?

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug antibodies at target dose Study results support that SAB-142 is well-positioned for re-dosing in outpatient setting for type 1 diabetes Results will be presented in an R&D webinar event today at 8:00 am ET; registration details below MIAMI, Jan. 28, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS ), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced positive topline data from a Phase 1 trial of SAB-142 in a single-ascending dose among healthy volunteers. The study met its primary objectives related to safety and pharmacodynamic activity enabling SAB-142 to advance to Phase 2b clinical development.

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

MIAMI, Jan. 23, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), announced today that the Company will host a Research and Development webinar on January 28, 2025 to discuss the topline data for Phase 1 clinical trial for its lead candidate, SAB-142. The webinar will feature presentations from SAB BIO's management team and T1D Key Opinion Leader (KOL) Michael Haller, MD, the division chief of the Pediatric Endocrinology Division at the University of Florida and Silverstein Family Eminent Scholar Chair in Pediatric Endocrinology.

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

See News Rankings

Charts implemented using Lightweight Charts™